Latest news with #Serranator®
Associated Press
03-04-2025
- Business
- Associated Press
Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family in EU and MENA Regions
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced its strategic partnership with 3comma Medical GmbH, a commercial services firm that specializes in bringing innovative medical device products to international markets. Under this collaboration, 3comma will serve as the exclusive international (OUS) distributor in EU and MENA regions for Cagent Vascular, leveraging its extensive network, industry expertise, and market insights to expedite the adoption of the Serranator® PTA Serration Balloon Product Family. This expansion builds upon the company's commercial success and growth in the US market. The Serranator is a groundbreaking therapy for the treatment of peripheral artery disease (PAD) and chronic limb threatening ischemia (CLTI). 'We are excited to join forces with 3comma to accelerate adoption in international markets,' said Paul Wilson, Chief Commercial Officer of Cagent Vascular. 'Partnering with 3comma marks an exciting step forward in expanding global access to the Serranator portfolio and delivering cutting-edge solutions to patients around the world. 3comma's deep commercial experience with peripheral vascular products and quality service will strengthen our commercial efforts to ensure we maximize growth opportunities and rapidly scale our presence to match international demand.' Mr. Wilson added, 'We're especially excited to make Serranator more accessible to physicians, providing them with a better tool to enhance patient care and drive improved outcomes. ' Marc Paris, CEO and Managing Partner of 3comma, expressed enthusiasm about the partnership: 'We are thrilled to partner with Cagent Vascular and bring Serranator to physicians worldwide. Cagent's commitment to delivering high-quality products for the treatment of PAD and CLTI will be a valuable addition to the institutions we serve. By combining our comprehensive distribution capabilities with Cagent's innovative offerings, we aim to optimize PAD and CLTI treatment across the globe.' Advancing Vascular Care with Innovative Serration Technology Cagent Vascular remains committed to advancing vascular care by delivering high-quality, clinically effective solutions that improve patient outcomes. The company's proprietary serration balloon technology is designed to optimize vessel preparation, enhance arterial expansion, and address challenging lesion morphologies in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI). The Serranator ® and Serranator SL-PRO™ PTA Serration Balloon Catheters are FDA-cleared, novel balloons using stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies with minimal recoil. By bringing a differentiated approach to vessel preparation, Cagent Vascular continues to support physicians in delivering optimal outcomes for patients with PAD and CLTI. SOURCE: Cagent Vascular Copyright Business Wire 2025. PUB: 04/03/2025 09:41 AM/DISC: 04/03/2025 09:41 AM
Yahoo
04-03-2025
- Business
- Yahoo
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
WAYNE, Penn., March 04, 2025--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE: TFX) and Abbott (NYSE: ABT). With a proven track record of driving revenue growth, expanding market share, and fostering strategic partnerships, he will play a critical role in scaling Cagent Vascular's commercial footprint. "Paul is an exceptional leader with a deep understanding of our industry and a strong vision for growth," said Brian Walsh, Chairman and CEO of Cagent Vascular. "As we continue to expand our presence and bring innovative solutions to the market, his expertise and leadership will be invaluable to driving our commercial success. His track record in commercial execution and strategic expansion of disruptive Peripheral technology aligns perfectly with our mission." "I am thrilled to join Cagent Vascular at such an exciting time in its growth journey," said Mr. Wilson. "The company has developed a truly innovative solution that addresses a critical need in vascular care. I look forward to working with this talented team to support the continued success of serration technology in clinical practice." Advancing Vascular Care with Innovative Serration Technology Cagent Vascular remains committed to advancing vascular care by delivering high-quality, clinically effective solutions that improve patient outcomes. The company's proprietary serration balloon technology is designed to optimize vessel preparation, enhance arterial expansion, and address challenging lesion morphologies in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI). The Serranator® and Serranator SL-PRO™ PTA Serration Balloon Catheters are FDA-cleared, novel balloons using stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies with minimal recoil. By bringing a differentiated approach to vessel preparation, Cagent Vascular continues to support physicians in delivering optimal outcomes for patients with PAD and CLTI. View source version on Contacts Lauren Pfeiffer, Director of Marketing and Communicationsinfo@ Sign in to access your portfolio
Yahoo
28-01-2025
- Business
- Yahoo
Cagent Vascular Initiates the Serranator® POINT FORCE Observational Registry
Study Will Enroll a Minimum of 500 Patients Across 30 United States Centers, Demonstrating the Benefits of Cagent's Unique Serration Balloon Angioplasty Technology in Real-World Clinical Cases WAYNE, Penn., January 28, 2025--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the start of the POINT FORCE Registry, a post-market clinical follow-up study of the Serranator® PTA Serration Balloon Catheter. This prospective, multicenter, single-arm study will enroll a minimum of 500 subjects at up to 30 centers in the United States. The objective of this study is to evaluate the safety and efficacy, under local standard of care, of Serration Angioplasty for the treatment of Peripheral Artery Disease (PAD) throughout the entire leg. The primary endpoint for this study is Device Success, defined as the achievement of successful delivery, balloon inflation and deflation, and retrieval of the study device with a post- Serranator® residual stenosis of ≤30%, as assessed by an independent angiographic core lab. Yale Cardiovascular Research Group in New Haven, CT, will serve as the corelab for this study. Led by national co-principal investigators S. Jay Mathews, MD, MS, Director Cardiac Catheterization Laboratory, PERT & Structural Heart at Manatee Memorial Hospital in Bradenton, FL and Michael Siah, MD, Director of Limb Salvage at University of Texas Southwestern (UTSW) Medical Center in Dallas, TX, this registry will build the body of clinical evidence for Serration Angioplasty. The first POINT FORCE patient was enrolled at UTSW by Dr. Siah. "We're excited to launch the POINT FORCE registry with the initial enrollment here at UTSW," Dr. Siah said, "Serranator® is a key part of our ATK and BTK treatment algorithm, and our team is eager to analyze this large, corelab-adjudicated dataset to capture the results of treating with Serranation across a wide spectrum of treatment strategies and clinical presentations." "We know from prior corelab-adjudicated studies that Serranator® provides an efficacious result for patients, with a very low rate of complication and mitigated recoil," stated Dr. Mathews, "What we endeavor to understand In POINT FORCE is the role Serranation can play in routine clinical practice. We anticipate reviewing Iliac, Fem-Pop, Infra-Pop, and Infra-Malleolar vessel territories, along with AV Access." Brian Walsh, Chairman and CEO of Cagent Vascular, added, "Despite having performed over 20,000 procedures, Serranator® remains a new and disruptive PAD therapy. We expect POINT FORCE will illuminate the benefits of Serranation and help share the impact in all common clinical algorithms. We're excited to get started and grateful for the support of our PIs and all participating centers." About Cagent Vascular, Inc. For more information, visit The Serranator® is an FDA-cleared, novel balloon using proprietary stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies. View source version on Contacts Cagent Communications and Media Contact:Lauren Pfeiffer+1 610-688-2006LPfeiffer@ Sign in to access your portfolio
